A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for treating cognitive symptoms in Parkinson’s disease, a condition currently ...
BioArctic AB (publ), a Swedish research-based biopharma company, announced that the first patient has been dosed with exidavnemab in the EXIST phase 2a study, in Parkinson’s disease patients ... key ...